Genetron
Genetron Health Q1 Revenues up 20 Percent
Driven by LDT sales, especially of its early liver cancer screening assay, HCCscreen, the company's core oncology business grew 53 percent year over year.
Genetron Health, JD Health Partner to Provide Liver, Lung Cancer Online Management Services
The companies will comarket Genetron's HCCScreen assay, while doctors in JD Health's online network will have the option to use its eight-gene lung cancer mutation assay.
Genetron Health, Siemens Healthineers Partner to Promote Lung Cancer Molecular Testing in China
The companies will work together to increase adoption of Genetron's sequencing platform and lung cancer diagnostic assay in Chinese hospitals.
The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.
Genetron Health Q4 Revenues Up 30 Percent
The company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.